Data Sheet (Cat.No.T35914)



Epitinib succinate

| Chemical Proper | ties |
|-------------------|---|
| CAS No. : | 2252334-12-4 |
| Formula: | C28H32N6O6 |
| Molecular Weight: | 548.59 » ¹ ¹ ¹ ¹ ¹ ¹ ¹ |
| Appearance: | no data available |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year |
| | |

| Biological Description | |
|-------------------------------|---|
| Description | Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer. |
| Targets(IC50) | EGFR |

| Solubility Information | |
|---------------------------|---|
| Solubility | DMSO: 1 mg/ml,Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| Preparing Stock Solutions | |

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|------------|
| 1 mM | 1.8229 mL | 9.1143 mL | 18.2285 mL |
| 5 mM | 0.3646 mL | 1.8229 mL | 3.6457 mL |
| 10 mM | 0.1823 mL | 0.9114 mL | 1.8229 mL |
| 50 mM | 0.0365 mL | 0.1823 mL | 0.3646 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Zhou et al. The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis. Journal of Clinical Oncology 2016 34:15_suppl, e20502-e20502

Zhou et al. Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 2013 31:15_suppl, e19042-e19042

Inhibitor • Natural Compounds • Compound Libraries • Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481